SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is surging following a better-than-expected final Medicare Advantage payment rate announcement for 2027, which exceeded initial projections and alleviated concerns over margin pressure. While some investors are skeptical of long-term regulatory headwinds and ongoing sector volatility, the community is actively debating whether this news marks a durable recovery catalyst or if the stock will face continued profit-taking.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is under intense pressure as investors express skepticism toward the company's high debt load and recent struggles with operational fundamentals. The community is actively debating whether current price levels present a deep-value buying opportunity or a warning sign of further downside as bearish sentiment among traders continues to mount.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is facing intense volatility and downward pressure as investors weigh delayed manufacturing milestones against speculative reports of strategic partnerships for AI-integrated AR glasses. The community remains deeply divided, with some traders betting on a reversal driven by share buybacks and potential breakthroughs, while others express frustration over persistent production bottlenecks and ongoing cash burn.

Investment Managers Series Trust II - Tradr 2X Short TSLA Daily ETF

Tradr 2X Short TSLA Daily ETF

TSLQ is trending as traders leverage the ETF to capitalize on high volatility and perceived overvaluation in TSLA, with the community actively debating the stock's fundamentals versus its ongoing price momentum. Investors are heavily focused on short-term hedging strategies and options positioning, while discussing the impact of speculative hype and institutional liquidity on the stock's recent performance.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending as investors digest a major strategic expansion, featuring a long-term supply agreement with Google for custom AI chips and an expanded collaboration with Anthropic. The community is actively debating the stock's long-term potential as an AI infrastructure leader, while weighing technical price action and recent market volatility against the company's strong fundamental position.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently facing intense community debate as investors weigh ongoing price volatility and bearish sentiment against its institutional adoption, including new tokenization pilots and enterprise integrations. While some users are frustrated by its recent market performance compared to broader crypto trends, others view the current price levels as a long-term accumulation opportunity driven by potential regulatory clarity and continued RWA infrastructure development.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending as investors weigh recent reports of its custom TPU chip developments and expanded AI compute partnerships with Anthropic against broader sector volatility. The community remains focused on the company's long-term infrastructure strategy, debating whether these AI-driven efficiency gains represent a fundamental shift in the chip demand landscape.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

Investors are closely monitoring a structural rotation out of mega-cap tech, with many questioning if the long-running momentum behind these dominant names is finally stalling. While some market participants express concerns over stretched AI valuations and cooling institutional sentiment, others remain focused on the potential for broader market participation as the Magnificent Seven face increased scrutiny and technical resistance.

nLIGHT, Inc. engages in the provision of semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It operates through the Laser Products and Advanced Development segments. The Laser Products segment designs, manufactures, and sells a range of semiconductor lasers and fiber lasers that are typically integrated into laser systems or manufacturing tools built by customers. The Advanced Development segment focuses on research, design, and prototyping of next-generation laser technologies, leveraging expertise in laser technology, development, beam control, and advanced optics. The company was founded by Scott H. Keeney, Mark DeVito, and Jason Farmer in June 2000 and is headquartered in Camas, WA.

nLIGHT Inc

nLIGHT is seeing significant investor attention following a robust earnings report that highlighted strong growth in aerospace and defense revenue, reinforcing the stock's role in critical military directed-energy programs. The community is actively tracking the potential for large-scale government contract awards related to defense initiatives like the Iron Beam, while simultaneously debating the impact of short selling activity and the stock's valuation as it enters a period of heightened operational focus.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean Ltd. is trending as investors weigh its massive contract backlog and the transformative Valaris merger against heightened geopolitical instability in the Middle East that threatens global energy supply chains. The community is actively debating the stock's potential for a short squeeze, given high short interest and rising offshore day rates, while some market participants monitor the stock's valuation disconnect compared to its surging intrinsic potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Novo Nordisk stated that its price cuts for Ozempic and Wegovy are intended to benefit insured patients.</li><li>The company said this will also benefit patients who pay out of pocket, but their costs are tied to the list price of these drugs.</li><li>Novo Nordisk said this applies to patients with high-deductible health plans or co-insurance benefit designs.</li></ul>Novo Nordisk AS (NVO) is planning to cut Ozempic and Wegovy prices in the U.S. by up to 50% starting in 2027.Ozempic and Wegovy prices will start at a list price of $675 a month, effective Jan. 1, 2027, according to the company. This is a 50% reduction when compared to the current list price of Wegovy, and about 35% cut for the list price of Ozempic.“Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States,” said Jamey Millar, Novo Nordisk’s Executive Vice President of U.S. operations.<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk shares</a> were down nearly 2% in Tuesday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory with message volumes at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">Who Will Benefit From These Lower Prices?</h2>Novo Nordisk stated that its price cuts for Ozempic and Wegovy are intended to benefit insured patients.This will also benefit patients who pay out of pocket, but whose costs are linked to the list price of these drugs. This applies to patients with high-deductible health plans or co-insurance benefit designs, the company said.Novo Nordisk added that Tuesday’s price cuts do not impact its direct-to-consumer and self-pay offerings of Ozempic and Wegovy.<h2 class="st-heading-2">Ozempic And Wegovy Prices For Cash-Paying Patients</h2>Novo Nordisk currently offers Wegovy for cash-paying patients, starting at $149 per month for the pill and $199 per month for the pen.Ozempic prices start at $199 a month for the first two months for new patients for 0.25 mg and 0.5 mg doses.Existing patients can get Ozempic in 0.25 mg, 0.5 mg, and 1 mg doses at $349 per month.All patients will have to pay $499 a month for the 2 mg dose of Ozempic.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 24% year-to-date and 56% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amd-stock-soars-on-meta-expanded-6-gigawatt-deal-for-amd-gpus/cZRvDZZR4Cb">AMD Stock Soars Pre-Market After Meta Expands Multi-Year AI Chip Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Still life of Novo Nordisk's Wegovy semaglutide tablets with injectable prescription weight loss medicines, Ozempic, and Wegovy

Novo Nordisk To Cut Ozempic, Wegovy Prices By Up To 50%

Ozempic and Wegovy will start at a list price of $675 a month, effective Jan. 1, 2027, according to the company.

Equity

<ul class="summary-bullets"><li>The company stated that the UBT251 trial conducted by United Laboratories showed statistically significant improvements when compared to placebo on key secondary endpoints.</li><li>Novo Nordisk stated that from a baseline mean body weight of 92.2 kg, the highest mean weight loss observed for people treated with UBT251 was 19.7%, compared to 2% in the placebo group.</li><li>The company’s Chief Scientific Officer, Martin Holst Lange, added that Novo Nordisk is looking forward to reporting data from a global trial with UBT251 next year.</li></ul>Novo Nordisk AS (NVO) on Tuesday announced that its phase 2 clinical trial of a new obesity drug in China has shown successful results.Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.However,&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk shares</a> declined nearly 3% in Tuesday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory with message volumes at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">UBT251 Trial Results Show Significant Improvements</h2>The company stated that the UBT251 trial conducted by United Laboratories showed statistically significant improvements compared with placebo on key secondary endpoints, including waist circumference, blood glucose, blood pressure, and lipids.The trial investigated the safety and efficacy of UBT251 at doses of 2 mg, 4 mg, and 6 mg.Novo Nordisk stated that from a baseline mean body weight of 92.2 kg, the highest mean weight loss observed for people treated with UBT251 was 19.7%, or about 17.5 kg, compared to 2% or 1.6kg in the placebo group after 24 weeks of treatment.“We are very encouraged by these data from the trial in China, which demonstrate the potential of UBT251 and its differentiated clinical profile and safety and tolerability profile,” said Novo Nordisk’s Chief Scientific Officer, Martin Holst Lange.Lange added that the company is looking forward to reporting data from a global trial with UBT251 next year.<h2 class="st-heading-2">Why Is NVO Stock Declining Pre-Market?</h2>Novo Nordisk shares continued to decline in Tuesday’s pre-market session. This is after a fall of more than 16% on Monday, following the company's announcement that CagriSema demonstrated 23% weight loss in people with obesity in the Redefine 4 trial,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-nvo-stock-falling-pre-market-today/cZRtZlKR4UC">failing to meet</a> its primary endpoint.According to TheFly, analysts at JPMorgan downgraded Novo Nordisk to ‘Neutral’ from ‘Overweight’, calling the CagriSema results “disappointing.”The firm also further reduced its CagriSema forecasts by up to 63% through 2030, expecting a more challenging uptake for the product given its "inferiority" to Eli Lilly and Co.’s (LLY) Zepbound.Analysts at Kepler Cheuvreux downgraded NVO to ‘Hold’ from ‘Buy’ and stated that the company’s Redefine 4 study was a “major negative surprise.”Nordea analysts also downgraded Novo Nordisk to ‘Hold’ from ‘Buy’, with the firm citing a lack of near-term catalysts following Monday’s obesity study results.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 23% year-to-date and 55% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/is-microsoft-down-current-status/cZRtw5dR4yV">Is Microsoft Down? MSFT 365 Error Reports Spike On Downdetector, Company Says It Is Investigating The Issue</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

NVO Stock Continues To Decline Pre-Market After Monday’s Crash Amid CagriSema Setback – But Tuesday Brings Some Hope From China

Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.

<ul class="summary-bullets"><li>The company stated that CagriSema failed to match tirzepatide in terms of effectiveness in its clinical trial.</li><li>People treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 23.0% after 84 weeks compared to 25.5% with tirzepatide 15 mg, according to Novo.</li><li>When measuring the treatment effect regardless of adherence, people treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 20.2% compared to 23.6% with tirzepatide at 84 weeks.</li></ul>Novo Nordisk AS (NVO) shares fell more than 14% in Monday’s pre-market trade after the company announced headline results from Redefine 4, an open-label phase 3 trial.Novo Nordisk stated that CagriSema demonstrated 23% weight loss in people with obesity, but it failed to meet its primary endpoint.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk</a> trended in the ‘extremely bearish’ territory at the time of writing.<h2 class="st-heading-2">CagriSema Fails To Match Tirzepatide In Effectiveness</h2>Novo Nordisk stated that CagriSema failed to match tirzepatide in terms of effectiveness in its clinical trial.The company said that people treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 23.0% after 84 weeks compared to 25.5% with tirzepatide 15 mg.When measuring the treatment effect regardless of adherence, people treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 20.2% compared to 23.6% with tirzepatide at 84 weeks.“CagriSema has the potential to be the first GLP-1/amylin-combination product to reach the market for people living with obesity, documenting that cagrilintide adds to the existing benefits of semaglutide and offers clinically meaningful additive weight loss effects superior to what has been observed with GLP-1 biology alone,” said Novo Nordisk’s Chief Scientific Officer and Executive Vice President, Martin Holst Lange.<h2 class="st-heading-2">Who Is CagriSema Aimed At?</h2>CagriSema is a once-weekly subcutaneous treatment that is being investigated by Novo Nordisk for adults with overweight or obesity issues. It is also being considered as a treatment for adults with type 2 diabetes.The treatment is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and semaglutide 2.4 mg.Novo Nordisk says CagriSema works by inducing weight loss by reducing hunger, increasing feelings of fullness, which helps people eat less and reduce their calorie intake.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 7% year-to-date and 46% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-replicate-most-tariffs-after-supreme-court-ruling-goldman-sachs/cZRNfSqR4xV">Trump Administration Can Replicate Most Of The Tariffs, Says Goldman Sachs Following Supreme Court Rebuke: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is NVO Stock Falling Pre-Market Today?

The company stated that CagriSema demonstrated 23% weight loss in people with obesity, failing to meet its primary endpoint.

Current Price	$23.17
Prev Close	$23.12
Open	$23.25
Dividend Yield	N/A
50-Day Moving Average	$23.48
Beta	N/A
Avg. Volume	514,733.82
PE Ratio	N/A

52-Week High	$24.18
52-Week Low	$19.38
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

FTHI
First Trust Exchange-Traded Fund VI - First Trust BuyWrite Income ETF

Feed

News

Sentiment

Fundamentals

Info

Latest FTHI News

FTHIFirst Trust Exchange-Traded Fund VI - First Trust BuyWrite Income ETF